Everything below concerns Freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
| Property | Value | Notes |
|---|---|---|
| Common separation technique | Reversed-phase HPLC | Separates mainly by hydrophobicity; gradient elution is typical. |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; also detects many organic impurities. |
| Identity confirmation method | LC-MS or MALDI-MS | Provides molecular mass; not a stand-alone quantitative purity measure. |
| Aggregate assessment method | Size-exclusion chromatography | Detects dimers, oligomers, and larger species. |
| Content assessment method | Amino acid analysis | Estimates peptide mass fraction after hydrolysis and separation. |
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
1-Acetyl-5-MeO-DMT, also known as "methyl amide 5-MeO-DMT" or as 1-acetyl-5-methoxy-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT. It is the 1-acetyl derivative of 5-MeO-DMT. The drug is a prodrug of 5-MeO-DMT with modified pharmacokinetic properties compared to 5-MeO-DMT in rodents. It is assumed to be cleaved into 5-MeO-DMT by amidase enzymes. Various analogues of 1-acetyl-5-MeO-DMT that are likewise 5-MeO-DMT or dimethyltryptamine (DMT) prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life. 1-Acetyl-5-MeO-DMT was first described in the literature in a patent by Terran Biosciences in 2023. It has been one of the major prodrug compounds highlighted from the patent.
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography. Arthur 'Blaine' Bowman was born in 1946 in Ogden, Utah, US. Around age 10, his family moved to Southern California, where he grew up. Bowman attended Brigham Young University in Provo, Utah in the physics program. As an undergraduate, he worked in the summer as an engineer at McDonnell Douglas, testing modules for the Apollo rocket. Bowman received his B.S. in physics in 1970. Next, Bowman worked as a product engineer at Motorola's Semiconductor Products Division in Phoenix, Arizona, where he became interested in business. He attended Stanford University's school of business from 1971 to 1973, receiving his M.B.A. in 1973. He then joined McKinsey & Company as a management consultant.
Lactobacillales (order) as the most abundant; primarily upstream of pnuC, and sometimes pncB or pnuC–nadR operons. Notable organisms include species of Fructobacillus and many other lactic acid bacteria. Planctomycetota (phylum), commonly upstream of nadA. Pseudomonadota, found in Pseudomonas laurylsulfatiphila and related species, upstream of an annotated nucleoside transporter. Actinobacteriota, in isolated instances from metagenome-assembled genomes. The prevalence of mini-NAD⁺-II riboswitches in lactic acid bacteria is thought to be functionally significant, as these organisms rely on various anaerobic fermentation strategies (e.g., lactic acid or ethanol production) to maintain a balanced NAD⁺/NADH ratio. The prevalence of mini-NAD⁺-II riboswitches in lactic acid bacteria is thought to be functionally significant, as these organisms rely on various anaerobic fermentation strategies (e.g., lactic acid or ethanol production) to maintain a balanced NAD⁺/NADH ratio.
When multiple antibodies are present, or when an antibody is directed against a high-frequency antigen, the normal antibody panel procedure may not provide a conclusive identification. In these cases, hemagglutination inhibition can be used, wherein a neutralizing substance cancels out a specific antigen. Alternatively, the plasma may be incubated with cells of known antigen profiles in order to remove a specific antibody (a process termed adsorption); or the cells can be treated with enzymes such as ficain or papain which inhibit the reactivity of some blood group antibodies and enhance others. The effect of ficain and papain on major blood group systems is as follows: Enhanced: ABO, Rh, Kidd, Lewis, P1, Ii Destroyed: Duffy (Fya and Fyb), Lutheran, MNS Unaffected: Kell People who have tested positive for an unexpected blood group antibody in the past may not exhibit a positive reaction on subsequent testing; however, if the antibody is clinically significant, they must be transfused with antigen-negative blood regardless.
In 1969, the Dubna team carried out chemical experiments on element 102 and concluded that it behaved as the heavier homologue of ytterbium. The Russian scientists proposed the name joliotium (Jo) for the new element after Irène Joliot-Curie, who had recently died, creating an element naming controversy that would not be resolved for several decades, with each group using its own proposed names. In 1992, the IUPAC-IUPAP Transfermium Working Group (TWG) reassessed the claims of discovery and concluded that only the Dubna work from 1966 correctly detected and assigned decays to nuclei with atomic number 102 at the time. The Dubna team are therefore officially recognized as the discoverers of nobelium, although it is possible that it was detected at Berkeley in 1959. This decision was criticized by Berkeley the following year, calling the reopening of the cases of elements 101 to 103 a "futile waste of time", while Dubna agreed with IUPAC's decision. In 1994, as part of an attempted resolution to the element naming controversy, IUPAC ratified names for elements 101–109. For element 102, it ratified the name nobelium (No) on the basis that it had become entrenched in the literature over the course of 30 years and that Alfred Nobel should be commemorated in this fashion. Because of outcry over the 1994 names, which mostly did not respect the choices of the discoverers, a comment period ensued, and in 1995 IUPAC named element 102 flerovium (Fl) as part of a new proposal, after either Georgy Flyorov or his eponymous Flerov Laboratory of Nuclear Reactions.
Sources: en.wikipedia.org
C5H12 + Cl2 → C5H11Cl + HCl Without zeolite catalysts, such reactions are unselective, so with n-pentane, the result is a mixture of the 1-, 2-, and 3-chloropentanes, as well as more highly chlorinated derivatives. Other radical halogenations can also occur.
South Africa Act 1909 Constitution of the Republic of South Africa 1961 Constitution of the Republic of South Africa 1983 Constitution of the Republic of South Africa 1993 Constitution of the Republic of South Africa 1996 Kahn, E. (1961). The New Constitution. Kruger, D.W. (1969). The Making of a Nation. May, H.J. (1949). The South African Constitution.
== History == In May 2020, artesunate was approved for medical use in United States. Prior to this approval, intravenous (IV) artesunate was only available through the Expanded Access program of the U.S. Food and Drug Administration (FDA), which allowed the Centers for Disease Control and Prevention (CDC) to provide IV artesunate to people in the U.S. with severe malaria and to people with uncomplicated malaria who are unable to take oral medications under an investigational new drug (IND) protocol. There has been no FDA-approved drug for treatment of severe malaria in the United States since the marketing of quinidine was discontinued by the manufacturer in March 2019. The safety and efficacy of IV artesunate for the treatment of severe malaria was primarily evaluated in a randomized controlled trial in Asia (Trial 1) and a supportive published randomized controlled trial in Africa (Trial 2). Trial 1 was conducted at 10 sites in Myanmar, Bangladesh, India, and Indonesia. Trial 1 enrolled 1,461 participants who received either IV artesunate or the comparator drug quinine and included 202 pediatric participants younger than 15 years. Trial 2 included 5,425 randomized pediatric participants younger than 15 years of age with severe malaria who were treated with artesunate or quinine. In both trials, the number of participants treated with artesunate who died in the hospital was significantly lower than the number who died in the control group treated with quinine. Trial 2 was conducted during 2005–2010 in nine African countries.
=== Government Palace === In his inauguration speech Castillo said he would not govern from the Government Palace, also known as the House of Pizarro, due to it being a colonial symbol. Additionally, Castillo said that he would turn the Government Palace into a museum. Castillo first governed from a temporary house in Breña, Peru, but he began to govern from the Government Palace due to legal issues involving the house. Governing from the Government Palace was announced as a temporary measure by Castillo. However, no further announcements on the Government Palace have been made.
== External links == "Papers of John B. Fenn, 1948–2010 (bulk 1970–1990)". Science History Institute. Click on 'Fenn Papers Finding Aid 2014' for finding aid to archive. Interview where John Fenn discusses the history of the development of the Electrospray Ionization method Annual Reviews Conversations Interview with John B. Fenn (video) John B. Fenn on Nobelprize.org including the Nobel Lecture December 8, 2002 Electrospray Wings for Molecular Elephants Dudley R. Herschbach and Charles E. Kolb, "John B. Fenn", Biographical Memoirs of the National Academy of Sciences (2014)
Sources: en.wikipedia.org
Facelift was certified gold by the Recording Industry Association of America (RIAA) for selling 500,000 copies on September 11, 1991, becoming the first album from Seattle's grunge movement to be certified gold. The band continued to hone its audience, opening for such artists as Iggy Pop, Van Halen, Poison, and Extreme. Facelift has since been certified triple-platinum by the RIAA, for shipments of 3,000,000 copies in the US. The concert at the Moore Theatre in Seattle on December 22, 1990, was recorded and released on VHS in mid-1991, as Live Facelift. It features five live songs and three music videos. The home video has been certified gold by the RIAA for sales exceeding 50,000 copies. In early 1991, Alice in Chains landed the opening slot for the Clash of the Titans tour with Anthrax, Megadeth, and Slayer, exposing the band to a wide metal audience but receiving mainly poor reception. Alice in Chains was nominated for a Best Hard Rock Performance Grammy Award in 1992 for "Man in the Box". Following the tour, Alice in Chains entered the studio to record demos for its next album, but ended up recording five acoustic songs instead. While in the studio, drummer Sean Kinney had a dream about "making an EP called Sap". The band decided "not to mess with fate", and on February 4, 1992, Alice in Chains released their second EP, Sap. The EP was released while Nirvana's Nevermind was at the top of the Billboard 200 charts, resulting in a rising popularity of Seattle-based bands, and of the term "grunge music". Sap was certified gold within two weeks.
According to a study published in 2017, the odds of contracting CJD for patients in Japan who received a Lyodura graft was at least 1 in 877 (~0.1%). In 2004, five Australian patients had been diagnosed with Creutzfeldt–Jakob disease after receiving Lyodura grafts. Due to the long latent period of Creutzfeldt–Jakob disease, epidemiologists remain uncertain how many people will be affected by the disease. B.Braun Melsungen and several other entities agreed to compensate the families of Japanese CJD victims for more than $600,000 each. An award-winning documentary was produced on the subject. The Canadian Broadcasting Corporation's The Fifth Estate segment, "Deadly Harvest", dealt with the product's history, sale in Canada, and health effects worldwide. The product has since been banned for use in Canada.
The development of the chemistry of alkaloids was accelerated by the emergence of spectroscopic and chromatographic methods in the 20th century, so that by 2008 more than 12,000 alkaloids had been identified. The first complete synthesis of an alkaloid was achieved in 1886 by the German chemist Albert Ladenburg. He produced coniine by reacting 2-methylpyridine with acetaldehyde and reducing the resulting 2-propenyl pyridine with sodium.
=== Books === Predictably Irrational: The Hidden Forces That Shape Our Decisions (2008; second edition in 2012). HarperCollins. ISBN 9780061353239 The Upside of Irrationality (2010). HarperCollins. ISBN 9780062008565 The Honest Truth about Dishonesty: How We Lie to Everyone – Especially Ourselves (2012; second edition in 2013). HarperCollins. ISBN 9780062298553 Behavioral Economics Saved My Dog: Life Advice for the Imperfect Human (2015). Oneworld. ISBN 9781780748177 Irrationally Yours: On Missing Socks, Pick-up Lines, and Other Existential Puzzles (2015). HarperCollins. ISBN 9780062380012 Payoff: The Hidden Logic That Shapes Our Motivations (2016). Simon & Schuster / TED. ISBN 9781501120053 Dollars and Sense: How We Misthink Money and How to Spend Smarter (2017). Co-authored with Jeff Kreisler. HarperCollins. ISBN 9780062651228 Small Change: Money Mishaps and How to Avoid Them (2018). Co-authored with Jeff Kreisler. Pan Macmillan. ISBN 9781509889167 Amazing Decisions: The Illustrated Guide to Improving Business Deals and Family Meals (2019, illustrated by Matt R. Trower), Farrar, Straus and Giroux.ISBN 9781466899544 Misbelief: What Makes Rational People Believe Irrational Things (2023), Bonnier Books UK. ISBN 9781785120787 Professor D Takes Control (2026). Charlesbridge. ISBN 978-1-62354-792-9
=== Physical Activity/Exercise === Along with diet, physical activity is also important for the management of diabetes. Not only does exercising regularly help manage blood sugar levels and weight, it helps reduce the risk of heart attack and stroke, reduces cholesterol and blood pressure levels, reduces risk of diabetes related complications, increases the effect of insulin, provides a boost in energy levels, helps reduce stress, and contributes to positive self-esteem. By exercising, the body becomes more sensitive to insulin, allowing for better absorption of glucose by the muscle cells, for up to 24 hours after exercise. In addition, studies have shown that physical activity, even below recommended amounts, has the ability to reduce risk of diabetic-related complications. In people with type 2 diabetes, the combination of aerobic ("cardio") exercise and strength training is effective. Aerobic exercise has been shown to largely improve HbA1c, and contributes to weight loss and the enhanced regulation of cholesterol and lipoproteins. This may be any form of continuous exercise that elevates breathing and heart rate, such as walking, swimming, or dancing. During the last 20 years, resistance training has gained recognition as an effective form of exercise for people with type 2 diabetes. A light walk after a meal (postprandial walking) is also recognized as effective in reducing postprandial glucose spikes in people with or at risk for type 2 diabetes. In youths with type 1 diabetes, there is an association between exercise and lower HBA1c.
Sources: en.wikipedia.org
RP-HPLC purity is the relative area of the main peptide peak compared with the total integrated peak area. It reflects ultraviolet-absorbing species under one set of separation conditions. It does not identify every impurity or measure biological activity.
Chromatographic conditions such as column chemistry, gradient slope, mobile-phase additives, and detection wavelength affect peak resolution. Sample preparation and integration rules also influence area percent values. Without a shared reference standard and validated method, direct comparisons remain uncertain.
Purity describes the proportion of the main peak among detected components. Peptide content measures the amount of the target peptide in a sample after accounting for counterions, water, and residual salts. A sample can have high chromatographic purity but lower net peptide content.
A certificate of analysis reports test results, methods, and specifications for a peptide lot. It often includes appearance, purity by chromatography, mass confirmation, and storage recommendations. It supports quality assessment but does not by itself guarantee suitability for every application.